Pascal Nieper

University Hospital of Cologne

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 20 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: the Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial

Petra Langerbeins,Sandra Robrecht,Pascal Nieper,Paula Cramer,Moritz Fuerstenau,Othman Al-Sawaf,Florian Simon,Anna-Maria Fink,Karl-Anton Kreuzer,Ursula Vehling-Kaiser,Eugen Tausch,Christof Schneider,Lothar Mueller,Michael Josef Eckart,Rudolf Schlag,Werner Freier,Tobias Gaska,Christina Balser,Marcel Reiser,Martina Stauch,Mark-Oliver Zahn,Steffen Doerfel,Peter Staib,Timo Behlendorf,Manfred Hensel,Holger Hebart,Holger Klaproth,Andreas Block,Ruediger Liersch, Ulrich Hauch,Bernhard Heinrich,Clemens-Martin Wendtner,Kirsten Fischer,Stephan Stilgenbauer,Barbara Eichhorst,Michael Hallek

JOURNAL OF CLINICAL ONCOLOGYno. 4 (2025)

Cited0Views0WOSBibtex

Post-transplant-cyclophosphamide Plus Everolimus As GvHD Prophylaxis in Refractory T- and B-cell Lymphoma

Tim Richardson, Hishan Tharmaseelan,Lukas Frenzel,Philipp Gödel,Moritz Fürstenau,Pascal Nieper,Till Braun, Daniel Schütte,Michael Hallek,Christof Scheid,Udo Holtick

Bone marrow transplantationno. 2 (2024): 244-246

Cited0Views0WOSNATUREBibtex

Second Primary Malignancies (spms) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of a Targeted Agent with an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

Ellinor Goergen,Julia von Tresckow,Adam Giza,Sandra Robrecht,Anna-Maria Fink,Kirsten Fischer,Othman Al-Sawaf,Moritz Fuerstenau,Florian Simon,Nadine Kutsch,Pascal Nieper,Eugen Tausch,Matthias Ritgen,Sebastian Boettcher,Karl-Anton Kreuzer,Stephan Stilgenbauer,Petra Langerbeins,Barbara Eichhorst,Michael Hallek,Paula Cramer

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S354-S355

Cited0Views0Bibtex

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Ellinor Goergen,Sandra Robrecht,Adam Giza,Can Zhang,Pascal Nieper,Florian Simon,Paula Cramer,Moritz Fürstenau,Othman Al-Sawaf,Nadine Kutsch,Anna Maria Fink,Ursula Vehling-Kaiser,Lothar Müller,Michael J. Eckart,Rudolf Schlag,Werner Freier,Tobias Gaska,Christina Balser,Marcel Reiser,Martina Beate Stauch,Clemens-Martin Wendtner,Eugen Tausch,Christof Schneider,Kirsten Fischer,Stephan Stilgenbauer,Barbara F. Eichhorst,Michael Hallek,Petra Langerbeins

Bloodno. Supplement 1 (2024): 1859-1859

Cited0Views0Bibtex

CLL-465 Second Primary Malignancies (spms) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of a Targeted Agent with an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

Ellinor Goergen, Julia v. Tresckow,Adam Giza,Sandra Robrecht,Anna-Maria Fink,Kirsten Fischer,Othman Al-Sawaf,Moritz Fürstenau,Florian Simon,Nadine Kutsch,Pascal Nieper,Eugen Tausch,Matthias Ritgen,Sebastian Böttcher,Karl-Anton Kreuzer,Stephan Stilgenbauer,Petra Langerbeins,Barbara Eichhorst,Michael Hallek,Paula Cramer

Clinical Lymphoma Myeloma and Leukemia（2024）

Cited0Views0Bibtex

Table S2 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

Ruth Flümann,Julia Hansen,Benedikt W. Pelzer,Pascal Nieper,Tim Lohmann,Ilmars Kisis,Tobias Riet,Viktoria Kohlhas,Phuong-Hien Nguyen,Martin Peifer,Nima Abedpour,Graziella Bosco,Roman K. Thomas,Moritz Kochanek,Jacqueline Knüfer,Lorenz Jonigkeit,Filippo Beleggia,Alessandra Holzem,Reinhard Büttner,Philipp Lohneis,Jörn Meinel,Monika Ortmann,Thorsten Persigehl,Michael Hallek,Dinis Pedro Calado,Markus Chmielewski,Sebastian Klein,Joachim R. Göthert,Bjoern Chapuy,Branko Zevnik,F. Thomas Wunderlich,Bastian von Tresckow,Ron D. Jachimowicz,Ari M. Melnick,Hans Christian Reinhardt,Gero Knittel

openalex（2023）

Cited0Views0Bibtex

Table S6 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

openalex（2023）

Cited0Views0Bibtex

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL

P. Langerbeins,S. Robrecht,P. Nieper,P. Cramer,M. Fürstenau,O. Al‐Sawaf,A. Fink,K. Kreuzer,U. Vehling‐Kaiser,E. Tausch,C. Schneider,L. Müller,R. Schlag,W. Freier,T. Gaska,C. Balser,M. Reiser,M. Stauch,M. Zahn,S. Dörfel,M. J. Eckart,P. Staib,T. Behlendorf,M. Hensel,H. Hebarth,H. Klaproth,A. Block,R. Liersch,U. Hauch,B. Heinrich,C. Wendtner,K. Fischer,S. Stilgenbauer,B. Eichhorst,M. Hallek

Hematological Oncologyno. S2 (2023): 56-58

Cited4Views0Bibtex

Supplementary Figures S1 to S12 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

openalex（2023）

Cited0Views0Bibtex

Table S4 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

openalex（2023）

Cited0Views0Bibtex

Author Statistics

#Papers: 20

#Citation: 51

H-Index: 4

G-Index: 5

Sociability: 5

Diversity: 1

Activity: 1

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn